The prolonged fast.
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
For patients suspected of hyperinsulinism (1), whose spells eluded blood glucose documentation, provocation of symptomatic hypoglycemia by food deprivation became de rigueur once insulinoma had been identified at the Mayo Clinic in 1927 (2) as the cause of this condition. The duration of fasting varied from 12–48 h until the 1950s when investigators at the same institution recommended prolonging the fast to 72 h in the asymptomatic patient (3). In the September 2000 issue of JCEM, Hirshberg et al. (4) question the necessity for extending the period of fasting beyond 48 h in patients being evaluated for a hypoglycemic disorder. They have confirmed previous reports that most persons with insulinoma have a positive fast within 48 h. The Mayo Clinic experience of positive fasts within 48 h in large series of patients with insulinoma has been reported as: 94% (n = 108, 1927–1965) (5) and 92% (n = 51, 1964–1975) (6). In the subsequent period, 1976 to the present, we have histological confirmation in 205 patients operated on for insulinoma. Among these, 170 underwent prolonged fasts according to a standard protocol. The fast was terminated within 12 h in 33%, 24 h in 65%, 36 h in 84%, 48 h in 93%, and 72 h in 99%. Two patients had negative fasts at 72 h; in one the fast remained negative through 96 h. Although a very rare event, negative 72-h fasts in insulinoma patients have been observed by others. Could any of these prolonged fasts have been terminated earlier without sacrificing diagnostic accuracy, as suggested by Hirshberg et al. (4)? The answer to this question is predicated partly on the purpose for which the prolonged fast is conducted. When the prolonged fast is done to determine the role of β-cell polypeptides in the genesis of previously documented hypoglycemia, the fast may be terminated when the plasma glucose is 55 mg/dL or less (7) because β-cell polypeptide levels are suppressed below that glucose level. Assuming that plasma glucose is being monitored on a frequent basis, there is no good reason for a fast done for that reason to be unduly prolonged. However, recognition of this purpose for the prolonged fast is relatively new (7). The classic end point of the prolonged fast has been the demonstration of Whipple’s triad. The latter requires knowledge of the current plasma glucose concentration and identification of concurrent neuroglycopenic symptoms. The decision to end a prolonged fast requires considerable judgement by the physician in attendance and is not amenable to retrospective review, except in the rare instances of egregious inattentiveness by the responsible physician. Could the prolonged fast be arbitrarily terminated at 48 h in the asymptomatic patient and an interpretation made later based on the plasma glucose and insulin concentrations, as suggested by the NIH investigators? To do so would preclude demonstration of Whipple’s triad, an important factor in the diagnosis of a hypoglycemic disorder. In addition, although a low plasma glucose is necessary, it is not sufficient to make a diagnosis of a hypoglycemic disorder because of the overlap between normal and hypoglycemic patients (7). Furthermore, even with the use of carefully generated criteria for hyperinsulinism, plasma insulin levels fall below the criterion for hyperinsulinemia in a small number of insulinoma patients in our experience and that of the NIH group. Although the criteria for hyperinsulinemia were generated from the 72-h fast (7, 8) and apply when the plasma glucose is low regardless of the duration of food deprivation the obverse, the demonstration of β-cell suppression in the nonhypoglycemic patient probably requires 72 h of fasting to generate conditions conducive to complete β-cell suppression. It is not known whether current criteria would apply at 48 h of fasting. Since an accurate diagnosis is so important because of implications for radiologic studies (some of which may be invasive) and major surgery, we take the position of conducting evaluations with great care and measuring not only all three β-cell polypeptides (insulin, C-peptide, and proinsulin) but also insulin surrogates such as β-hydroxybutyrate and plasma glucose response to iv glucagon. We are pleased that the NIH has followed our lead in measuring plasma proinsulin directly. However, due to limitations in their analysis, which failed to relate the proinsulin concentrations to glucose concentrations in insulinoma patients vs. controls, a diagnostic criterion could not be generated by them. Recommendations regarding optimal duration of the prolonged fast based solely on experience with insulinoma fails to take into consideration that when a prolonged fast is undertaken in a patient suspected to have a hypoglycemic disorder the presence of and, indeed, the nature of that disorder is not known. For instance, in recent years we have subjected noninsulinoma hypoglycemic patients to the prolonged fast who subsequently had the following diagnoses: ins
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An occasional patient with an insulinoma may not fulfill these criteria even during a 72-h fast (15,60), and a few have plasma insulin levels below 3 U/ml (18 pmol/liter) during fasting hypoglycemia, but plasma C-peptide levels are usually 0.6 ng/ml (0.2 mmol/liter) or greater and plasma proinsulin levels are usually 5.0 pmol/liter or greater in the latter patients.”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [60]
In the citing paper
“Most, but not all (60), patients with an insulinoma fulfill these diagnostic criteria in less than 72 h.”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [60]
In the citing paper
“Indeed, that occurs in less than 24 h in about two thirds, and in less than 48 h in the vast majority, of affected patients (60).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [60]
In the citing paper
“Of note, it is helpful to know that 95% of patients with insulinoma meet end-of-fast criteria by 48 h, but the fast may be extended to 72 h as 7% of patients with proven insulinomas developed hypoglycemia after 48 h [87,88].”
From Non-Diabetic Hypoglycemia: Evaluation and Management in Adults (2025) · cites this paper as [88]
Citations
Cites
CARCINOMA OF THE ISLANDS OF THE PANCREAS: HYPERINSULINISM AND HYPOGLYCEMIA
WILDER, R. M., ALLAN, F. N., POWER, M. H., & ROBERTSON, H. E. (1927) · Journal of the American Medical Association · doi:10.1001/jama.1927.02690050014007 · Cited by 443
HYPERINSULINISM AND DYSINSULINISM
HARRIS, S. (1924) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1924.02660100003002 · Cited by 326
Service, F. J., Dale, A. J. D., Elveback, L. R., & JIANG, N.-S. (1976) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(25)07100-9 · Cited by 288
Self-citationForty-Eight-Hour Fast: The Diagnostic Test for Insulinoma
Hirshberg, B., Livi, A., Bartlett, D. L., Libutti, S. K., Alexander, H. R., Doppman, J. L., Skarulis, M. C., & Gorden, P. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.9.6807 · Cited by 256
(1976) · PubMed · Cited by 244
Laroche, G. P. (1968) · Archives of Surgery · doi:10.1001/archsurg.1968.01330230071009 · Cited by 77
Cited by
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Cryer, P. E., Axelrod, L., Grossman, A. B., Heller, S. R., Montori, V. M., Seaquist, E. R., & Service, F. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1410 · Cited by 1,277
Self-citationFrancis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Diagnosis and Management of Insulinoma
Okabayashi, T. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i6.829 · Cited by 482
Well-Differentiated Pancreatic Tumor/Carcinoma: Insulinoma
de Herder, W. W., Niederle, B., Scoazec, J.-Y., Pauwels, S., Klöppel, G., Falconi, M., Kwekkeboom, D. J., Öberg, K., Eriksson, B., Wiedenmann, B., et al. (2006) · Neuroendocrinology · doi:10.1159/000098010 · Cited by 295
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers
O’Toole, D., Grossman, A., Gross, D., Delle Fave, G., Barkmanova, J., O’Connor, J., Pape, U.-F., & Plöckinger, U. (2009) · Neuroendocrinology · doi:10.1159/000225948 · Cited by 268
Tucker, O. N., Crotty, P. L., & Conlon, K. C. (2006) · British Journal of Surgery · doi:10.1002/bjs.5280 · Cited by 202
Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment
Ro, C., Chai, W., Yu, V. E., & Yu, R. (2013) · Chinese Journal of Cancer · doi:10.5732/cjc.012.10295 · Cited by 184
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers
Oberg, K., Couvelard, A., Delle Fave, G., Gross, D., Grossman, A., Jensen, R. T., Pape, U.-F., Perren, A., Rindi, G., Ruszniewski, P., et al. (2017) · Neuroendocrinology · doi:10.1159/000472254 · Cited by 176
Biochemistry of neuroendocrine tumours
de Herder, W. W. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2006.12.002 · Cited by 161
Antwi, K., Fani, M., Heye, T., Nicolas, G., Rottenburger, C., Kaul, F., Merkle, E., Zech, C. J., Boll, D., Vogt, D. R., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4101-5 · Cited by 124
Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
Kanakis, G., & Kaltsas, G. (2012) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2012.12.006 · Cited by 127
Role of biomarker tests for diagnosis of neuroendocrine tumours
Hofland, J., Zandee, W. T., & de Herder, W. W. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0082-5 · Cited by 126
Advances in the diagnosis and management of hyperinsulinemic hypoglycemia
Kapoor, R. R., James, C. T., & Hussain, K. (2009) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet1046 · Cited by 113
“This prolonged fasting test can detect up to 99% of insulinomas”
Won, J. G. S., Tseng, H., Yang, A., Tang, K., Jap, T., Lee, C. H., Lin, H., Burcus, N., Pittenger, G., & Vinik, A. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02629.x · Cited by 109
Pancreatic insulinoma: current issues and trends.
Vaidakis, D., Karoubalis, J., Παππά, Θ., Piaditis, G. P., & Zografos, G. N. (2010) · Hepatobiliary & pancreatic diseases international · Cited by 112
van Schaik, E., van Vliet, E. I., Feelders, R. A., Krenning, E. P., Khan, S., Kamp, K., Valkema, R., van Nederveen, F. H., Teunissen, J. J. M., Kwekkeboom, D. J., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1563 · Cited by 99
Occult sporadic insulinoma: Localization and surgical strategy
Abboud, B., & Boujaoude, J. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.657 · Cited by 103
Approach to the Patient: Insulinoma
Hofland, J., Refardt, J. C., Feelders, R. A., Christ, E., & de Herder, W. W. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad641 · Cited by 91
Surgical treatment of insulinomas
Finlayson, E. V. A., & Clark, O. H. (2004) · Surgical Clinics of North America · doi:10.1016/j.suc.2004.02.004 · Cited by 90
“A substantial proportion of patients—33%—become hypoglycemic within 12 hours, 65% within 24 hours, 84% within 36 hours, 93% within 48 hours, and 99% within 72 hours [7].”
BackgroundKar, P., Price, P., Sawers, S., Bhattacharya, S., Reznek, R. H., & Grossman, A. B. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1430 · Cited by 79
Druce, M. R., Muthuppalaniappan, V. M., O’Leary, B., Chew, S. L., Drake, W. M., Monson, J. P., Akker, S. A., Besser, M., Sahdev, A., Rockall, A., et al. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0056 · Cited by 79
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors
Pavel, M., & de Herder, W. W. (2017) · Neuroendocrinology · doi:10.1159/000457957 · Cited by 79
The Use of Somatropin (Recombinant Growth Hormone) in Children of Short Stature
Mehta, A., & Hindmarsh, P. C. (2002) · Pediatric Drugs · doi:10.2165/00128072-200204010-00005 · Cited by 58
Fottner, C., Ferrata, M., & Weber, M. M. (2017) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-017-9438-8 · Cited by 64
“The accuracy of the prolonged fast can be improved by including C-peptide, proinsulin and β-Hydroxybutyrate [35].”
BackgroundContinuous glucose monitoring in patients with insulinoma
Munir, A., Choudhary, P., Harrison, B., Heller, S., & Newell‐Price, J. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03161.x · Cited by 49
Hyperinsulinaemic Hypoglycaemia
Arya, V. B., Mohammed, Z. K., Blankenstein, O., de Lonlay, P., & Hussain, K. (2014) · Hormone and Metabolic Research · doi:10.1055/s-0034-1367063 · Cited by 50
Kann, P. H., Ivan, D., Pfützner, A., Forst, T., Langer, P., & Schaefer, S. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0117 · Cited by 38
“A fasting test of 48 h has been proposed (13), but this test duration remains controversial (2).”
Service, F. J., & O’Brien, P. C. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0033 · Cited by 34
Self-citationPlöckinger, U., & Wiedenmann, B. (2002) · Digestive Diseases · doi:10.1159/000063164 · Cited by 33
Eckert‐Norton, M., & Kirk, S. E. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-v98i10-39a · Cited by 32
“The 72-hour fast is usually successful in capturing hypoglycemia in patients with insulinoma, as 65% of patients will experience hypoglycemia within 24 hours, 93% within 48 hours, and 99% within 72-hours (51).”
BackgroundWiesli, P., Schmid, C., Perren, A. A., Pfammatter, T., Spinas, G. A., & Keller, U. B. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03346277 · Cited by 31
The incidence of insulinoma in Western Sweden between 2002 and 2019
Svensson, E., Muth, A., Hedenström, P., & Ragnarsson, O. (2022) · Annals of Gastroenterology · doi:10.20524/aog.2022.0707 · Cited by 30
“The same 72-h fasting test protocol, which is the gold standard for confirmation of insulinoma [17-19], was used during the entire study period.”
MethodClinical Presentation and Diagnostic Approach to Hypoglycemia in Adults Without Diabetes Mellitus
Palani, G., Stortz, E., & Moheet, A. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2022.11.010 · Cited by 29
Leroy‐Freschini, B., Amodru, V., Addeo, P., Sebag, F. A., Vix, M., Brunaud, L., Klein, M., Bahougne, T., Bachellier, P., Castinetti, F., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4245-3 · Cited by 30
Minimally Invasive Techniques for Resection of Pancreatic Neuroendocrine Tumors
Ranvier, G. G. F., Shouhed, D., & Inabnet, W. B. (2015) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2015.08.009 · Cited by 26
“At present, biochemical measurement of plasma glucose, insulin, C peptide, and proinsulin levels during a 72-hour fast can detect up to 99% of insulinomas and has become the gold standard of diagnosis.(16) However, in more than 97% of cases, biochemical testing in conjunction with a supervised 48-hour fast is sufficie…”
BackgroundZhao, K., Patel, N., Kulkarni, K., Gross, J., & Taslakian, B. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103091 · Cited by 26
Diagnosis of insulinoma in a patient with hypoglycemia without obvious hyperinsulinemia
Coelho, C., Druce, M. R., & Grossman, A. B. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.198 · Cited by 26
“The 72 h fast is the gold standard test for the diagnosis of insulinomas”
MethodPreoperative Localisation and Surgical Management of Insulinoma: Single Centre Experience
Varma, V., Tariciotti, L., Coldham, C., Taniere, P., Buckels, J. A. C., & Bramhall, S. R. (2011) · Digestive Surgery · doi:10.1159/000322405 · Cited by 23
Almeida, M. Q., Machado, M. C. C., Corrêa‐Giannella, M. L., Giannella‐Neto, D., & Pereira, M. A. A. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03344176 · Cited by 23
Dhar, J., Samanta, J., Nabi, Z., Aggarwal, M., Facciorusso, A., Bellocchi, M. C. C., & Crinò, S. F. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2321938 · Cited by 22
Fast test: Clinical practice and interpretation
Agin, A., Charrié, A., Chikh, K., Tabarin, A., & Vezzosi, D. (2013) · Annales d Endocrinologie · doi:10.1016/j.ando.2013.05.003 · Cited by 21
“There has been hown to be no diagnostic benefit in continuing to 96 hours’ asting [5].”
BackgroundInfluentialAssessment of hyperinsulinaemia at the termination of the prolonged fast
Wiesli, P., Brändle, M., Zapf, J., Seiler, H., Zwimpfer, C., Spinas, G. A., & Schmid, C. (2004) · Clinica Chimica Acta · doi:10.1016/j.cccn.2003.12.023 · Cited by 21
Comparison of the diagnostic accuracy of the current guidelines for detecting insulinoma
Dauben, L., Simon, M., Straßburger, K., Burkart, V., Weber, K. S., Schinner, S., Roden, M., & Müssig, K. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-0879 · Cited by 19
Value of 68Ga-DOTATOC and Carbidopa-Assisted 18F-DOPA PET/CT for Insulinoma Localization
Impériale, A., Boursier, C., Sahakian, N., Ouvrard, É., Chevalier, E., Sebag, F. A., Addeo, P., & Taïeb, D. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262401 · Cited by 19
“In adults with hypoglycemia or suggestive symptoms, the diagnosis of hyperinsulinemic hypoglycemia relies on a positive fasting test (1).”
BackgroundChristiansen, E., & Vestergaard, H. (2008) · Gynecological Endocrinology · doi:10.1080/09513590802210931 · Cited by 19
“However, in some patients prolonged fasting for 72 h is necessary for the fulfillment of these well-established criteria [16,17].”
BackgroundKann, P. H., Moll, R., Bartsch, D. K., Pfützner, A., Forst, T. M., Tamagno, G., Goebel, J. N., Fourkiotis, V., Bergmann, S. R., & Collienne, M. (2016) · Endocrine · doi:10.1007/s12020-016-1179-z · Cited by 19
“This issue suggests that the definition of the fasting test diagnostic criteria may be challenging and cases with inconclusive or borderline results are not uncommon [24, 25].”
Challis, B., Powlson, A., Casey, R. T., Pearson, C., Lam, B., Ma, M. K. L., Pitfield, D., Yeo, G. S. H., Godfrey, E. M., Cheow, H., et al. (2017) · Endocrine Connections · doi:10.1530/ec-17-0076 · Cited by 19
Abnormalities of proinsulin processing in functioning insulinomas: clinical implications
Wiesli, P., Perren, A., Saremaslani, P., Pfammatter, T., Spinas, G., & Schmid, C. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02095.x · Cited by 15
“These properties of normal β -cells allow healthy individuals to fast for 72 h without the occurrence of hypoglycaemia (Service & Natt, 2000) and explain that no significant increase in insulin concentration is observed during the arterial stimulation and hepatic venous sampling (ASVS) test when…”
BackgroundMechanism and recent updates on insulin-related disorders
Kumar, S., Senapati, S., Bhattacharya, N., Bhattacharya, A., Maurya, S. K., Husain, H., Bhatti, J. S., & Pandey, A. K. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i25.5840 · Cited by 21
Hypoglycemia - Causes and Occurrences
Rigobelo, E. C. (2011) · InTech eBooks · doi:10.5772/864 · Cited by 17
Insulinoma in a Patient with Normal Results from Prolonged Fast and Glucagon-Induced Hypoglycemia
Soh, A. W. E., & Kek, P. C. (2010) · Endocrine Practice · doi:10.4158/ep10073.cr · Cited by 18
Insulinoma and anaesthetic implications
Goswami, J., Somkuwar, P., & Naik, Y. (2012) · Indian Journal of Anaesthesia · doi:10.4103/0019-5049.96301 · Cited by 17
“In this test, at a plasma glucose level of 40–45 mg/dL, the patient is asked to undergo light exercise for 15–30 min even if there is no hypoglycaemic symptom.[5,16,17] Then, the plasma glucose measurement is repeated.”
BackgroundDiagnostics and treatment of insulinoma
KOREN, S. K. M. (2015) · Neoplasma · doi:10.4149/neo_2015_083 · Cited by 20
“The pathophysiological feature of this test is the fail to suppress insulin secretion during episodes of hypoglycemia [37].”
BackgroundWiesli, P., Brändle, M., Schwegler, B., Lehmann, R., Spinas, G. A., & Schmid, C. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.01060.x · Cited by 17
Case 23-2018: a 36-year-old man with episodes of confusion and hypoglycemia
Wexler, D. J., Macias-Konstantopoulos, W., Forcione, D. G., Xiong, L., Cauley, C. E., & Pierce, K. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmcpc1802828 · Cited by 16
Clinical Implications of Various Criteria for the Biochemical Diagnosis of Insulinoma
Ahn, C. H., Kim, L.-K., Lee, J. E., Jung, C.-H., Min, S.-H., Park, K. S., Kim, S. Y., & Cho, Y. M. (2014) · Endocrinology and Metabolism · doi:10.3803/enm.2014.29.4.498 · Cited by 14
Insulinoma—new insights into an old disease
Davì, M. V., & Falconi, M. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.99 · Cited by 14
A Rare Case of Insulinoma Presenting with Postprandial Hypoglycemia
Leung, V. (2014) · American Journal of Case Reports · doi:10.12659/ajcr.891336 · Cited by 14
“To obtain documentation of hypoglycemia, it may be necessary to perform provocative testing such as a 72-hour fast, mixed-meal test, or supervised exercise to simulate hypoglycemic conditions if a spontaneous episode is not observed [3].”
MethodEndogenous hyperinsulinemic hypoglycemia: case series and literature review
Zhang, C., Zhang, H., & Huang, W. (2022) · Endocrine · doi:10.1007/s12020-022-03268-5 · Cited by 13
“Although a 72-h starvation induction test is recommended as the biochemical golden standard to diagnose insulinoma [6], the most commonly used approach is opportune blood testing of plasma glucose, insulin, and C-peptide levels during hypoglycemic episodes [7].”
MethodShirota, T., Nagakawa, Y., Sahara, Y., Takishita, C., Hijikata, Y., Hosokawa, Y., Nakajima, T., Osakabe, H., Katsumata, K., & Tsuchida, A. (2018) · Gland Surgery · doi:10.21037/gs.2017.11.06 · Cited by 12
“Vasoactive intestinal peptideomas are exceedingly rare tumors, with an estimated incidence of only 1 in 10 million per year (17).”
BackgroundDifferentiation of Insulin Secretion Patterns in Insulinoma
Saddig, C., Goretzki, P. E., & Starke, A. A. R. (2008) · World Journal of Surgery · doi:10.1007/s00268-007-9450-3 · Cited by 12
“The supervised fasting test has been established as the standard endogenous suppression test for insulinoma [1, 2, 4, 11 , 23].”
MethodUeda, K., Kawabe, K., Lee, L., Tachibana, Y., Fujimori, N., Igarashi, H., Oda, Y., Jensen, R. T., Takayanagi, R., & Ito, T. (2017) · Pancreas · doi:10.1097/mpa.0000000000000772 · Cited by 12
“Although the 72-hour fasting test is considered as the criterion standard for diagnosis of the presence of insulinoma, this test poses a substantial burden on both patients and medical staff.(6) It has been proposed that shortening the fast”
BackgroundResult69-Year-Old Man With Recurrent Episodes of Confusion and Diaphoresis
Donegan, D. M., & Vella, A. V. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.09.006 · Cited by 11
“It is the test of choice to investigate hypoglycemia if Whipple triad has not been documented or if there is uncertainty regarding the cause of the hypoglycemia.(2) In the current case, a hypoglycemic disorder has been documented, as has the fact that it is insulin mediated (nonsuppressed insulin and suppressed b-hydr…”
BackgroundNon-Diabetic Hypoglycemia: Evaluation and Management in Adults
Looi, E., & Lawler, H. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134393 · Cited by 13
“Of note, it is helpful to know that 95% of patients with insulinoma meet end-of-fast criteria by 48 h, but the fast may be extended to 72 h as 7% of patients with proven insulinomas developed hypoglycemia after 48 h [87,88].”
Investigation and Causes of Spontaneous (Non-Diabetic) Hypoglycaemia in Adults: Pitfalls to Avoid
Elghobashy, M., Gama, R. M., & Sulaiman, R. A. (2023) · Diagnostics · doi:10.3390/diagnostics13203275 · Cited by 10
CGM for insulinoma screening: a prospective and observational case-control study
Ma, J., Huang, X., Zhao, J., Lu, J., Lu, W., Bao, Y., Zhou, J., & Han, J. (2021) · Endocrine Related Cancer · doi:10.1530/erc-20-0447 · Cited by 12
Service, F. J. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-293-7_10 · Cited by 10
Self-citationHomeostasis Model Assessment of β-Cell Function for Diagnosis of Insulinoma
Bódis, K. B., Schön, M., Dauben, L., Wilker, M., Straßburger, K., Burkart, V., Roden, M., & Müssig, K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad618 · Cited by 9
Aida, A., & Noto, H. (2022) · American Journal of Case Reports · doi:10.12659/ajcr.936723 · Cited by 9
“In adults with symptoms of neuroglycopenia and confirmed hypoglycemia, the criterion standard for biochemical diagnosis is the measurement of PG, insulin, C peptide, and proinsulin levels during a 72-h fasting period; according to Service et al [12], up to 99% of insulinomas can be detected using this prolonged fastin…”
MethodEdwards, K., Portilla, L. D. L., Mirza, F., & Luthra, P. (2019) · AACE Clinical Case Reports · doi:10.4158/accr-2019-0148 · Cited by 9
“It is likely that our patient falls into this group (13).”
BackgroundNesidioblastosis del adulto coexistente con insulinoma
Restrepo, K., Garavito, G., Rojas, L., Romero, A., Neira, F., Oliveros, R., & Abisambra, N. (2009) · Revista Colombiana de Cancerología · doi:10.1016/s0123-9015(09)70152-0 · Cited by 8
Ritzel, R. A., Isermann, B., Schilling, T., Knaebel, H., B�chler, M. W., & Nawroth, P. P. (2004) · The Review of Diabetic Studies · doi:10.1900/rds.2004.1.42 · Cited by 9
“Prolonged fasting is a sensitive procedure for detection of endogenous hyperinsulinism (sensitivity >90 %) [3] and is routinely employed as the initial test to detect inappropriately elevated insulin secretion as the cause for recurrent hypoglycemia.”
BackgroundPeptide Hormones as Tumor Markers in Clinical Practice
Sun, Q., & Zhao, Z. (2017) · The Enzymes · doi:10.1016/bs.enz.2017.09.001 · Cited by 8
Vaezi, M. A., Nekoufar, S., Robati, A. K., Salimi, V., & Tavakoli‐Yaraki, M. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02368-7 · Cited by 8
“This method has a 99% success rate in identifying these patients [71].”
Vaidya, A., Kaiser, U. B., Levy, B. D., & Loscalzo, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmcps0903869 · Cited by 8
Endokrine Tumoren des gastroenteropankreatischen Systems
Arnold, R., Langer, P., Rothmund, Μ., Klöppel, G., Kann, P. H., Heverhagen, J. T., Fendrich, V., Bartsch, D. K., Rinke, A., Müller, X., et al. (2012) · Springer eBooks · doi:10.1007/978-3-642-14285-7_5 · Cited by 8
Diagnosis and Treatment of Insulinomas in the Adults
Vezzosi, D., Bennet, A., Maïza, J.-C., Buffet, A., Grunenwald, S., Fauvel, J., Courbon, F., Otal, P., Carrère, N., & Caro, P. (2011) · InTech eBooks · doi:10.5772/17452 · Cited by 8
“…patients such plasma glucose concentrations are reached within the first 48 hours of the test (Hirshberg et al. 2000; Vezzosi et al. 2007), though the 72 hour-fast test was reported to be necessary to provide a clear diagnostic conclusion in a few patients (Service 1999; Service & Natt 2000).”
Reynolds, L. R., Park, A., Miller, R. E., & Karounos, D. G. (2002) · Endocrine Practice · doi:10.4158/ep.8.5.329 · Cited by 7
Clinicopathological Characteristics and Non-Adhesive Organ Culture of Insulinomas
Hoem, D., Jensen, D., Steine, S. J., Thorsen, T. E., Viste, A., & Molven, A. (2008) · Scandinavian Journal of Surgery · doi:10.1177/145749690809700106 · Cited by 6
Short fasting test as a reliable and effective tool to diagnose insulinoma
Mikovic, N., Mazzilli, R., Zamponi, V., Russo, F., Mancini, C., Mori, F., Bollanti, L., Conti, F., Motta, C., Monti, S., et al. (2024) · Endocrine · doi:10.1007/s12020-024-03759-7 · Cited by 7
“Through several series of cases of insulinoma, the Mayo clinic experience [14] concluded that the 72 h test was necessary to exclude false negative results in the few patients diagnosed on the 3 rd day of the fast.”
BackgroundPallais, J. C., Blake, M. A., & Deshpande, V. (2012) · New England Journal of Medicine · doi:10.1056/nejmcpc1114037 · Cited by 6
Insulinoma presenting with postprandial hypoglycemia and a low body mass index: A case report
Prídavková, D., Samoš, M., Kyčina, R., Adamicová, K., Kalman, M., Belicová, M., & Mokáň, M. (2020) · World Journal of Clinical Cases · doi:10.12998/wjcc.v8.i18.4169 · Cited by 7
Prieto, C., Builes-Montaño, C. E., Toro, C. M. A., Manotas-Echeverry, C., Cadavid, J. C. P., Álvarez-Payares, J. C., & Arrieta, L. A. R. (2022) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2022_003484 · Cited by 6
“Some series have reported a positivity rate of 93% after fasting for 48 hours, and 99% at 72 hours ([7]).”
BackgroundYu, J., Liu, Y., Lyu, L., Zhao, Y. Z., Qi, M., Ping, F., Xu, L., Li, W., Xu, Q., Zhang, H., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.994707 · Cited by 6
“The prolonged 72-h fasting test is the classic diagnostic test for hypoglycemia (4, 5).”
MethodSurgery in overweight patients with insulinoma: effects on weight loss
Dai, H., Xu, Q., Hong, X., Wang, X., Pang, H., Wu, W., & Zhao, Y. (2017) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2017.1335768 · Cited by 6
“The diagnosis of insulinoma was based on the following criteria: (1) typical symptoms of hypoglycemia which resolved with glucose ingestion; (2) the gold standard for the diagnosis of insulinoma: a 72-h fasting glucose test [23] and/or low blood glucose with corresponding high insulin and C peptide levels; (3) localiz…”
Method“Riding high on low fuel” - Our experience with endogenous hyperinsulinemic hypoglycemia
George, B., Manjunath, P., Mathew, V., Bantwal, G., & Ayyar, V. S. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_174_17 · Cited by 7
“The supervised 72 h fast is recognized as the gold standard test to rule out endogenous hyperinsulinemia; however, about two-thirds of patients with documented insulinoma develop hypoglycemia within the first 24 h.[18] A recent study by Anakal et al.”
BackgroundGastro-Entero-Pancreatic Neuroendocrine Tumors (GEP-Nets): A Review
Yi, C. C. X. (2013) · Journal of Gastrointestinal & Digestive System · doi:10.4172/2161-069x.1000154 · Cited by 6
“For insulinoma, supervised 72-Hour Fast is verified as the gold standard inestablishinga biochemical diagnosis [77], although some groups propose a shorter fast of 48h [78,79].”
MethodAdult spontaneous hypoglycaemia
Griffiths, M., & Gama, R. M. (2005) · British Journal of Hospital Medicine · doi:10.12968/hmed.2005.66.5.18421 · Cited by 7
Neuroendocrine Tumor Syndromes
Yu, R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00150-5 · Cited by 6
Eichelberger, G. S., Carbono, J., Field, Z., Kainaur, K., & Montalvo, F. (2020) · Case Reports in Endocrinology · doi:10.1155/2020/8879776 · Cited by 5
Hiperinsulinismo endógeno: revisão e seguimento de 24 casos
Felício, J. S., Martins, C. L. E. L. P., Semer, M., Kalinin, L. B., Nery, M., Machado, M. C. C., & Liberman, B. (2012) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302012000200001 · Cited by 7
Hypoglycemia: A tale of three causes
Narla, R. R., Hashimoto, T., Kelly, K. A., & Heaney, A. P. (2016) · Journal of Clinical and Translational Endocrinology Case Reports · doi:10.1016/j.jecr.2016.04.001 · Cited by 5
“He was admitted for a 72 hour fast (Figure 1) to further evaluate the mechanism of his hypoglycemia [3].”
BackgroundAcute Diabetic Emergencies, Hypoglycemia, and Glycemic Control
Chansky, M. E., & Haddad, G. (2008) · Elsevier eBooks · doi:10.1016/b978-032304841-5.50061-3 · Cited by 6
Anthropometric Features are not Predictive of 72-Hour Fast Duration in Insulinomas
Donegan, D. M., Jakubíková, I., & Vella, A. V. (2017) · Endocrine Practice · doi:10.4158/ep171872.or · Cited by 5
“hydroxybutyrate at fast termination (mmol/L) Median tumor diameter, mm (range) 14 (1- 97) 14 (6-97) 15 (1-90)”
BackgroundCryer, P. E. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00034-1 · Cited by 7
Grygiel, K., Szmidt, J., Jeleńska, M., & Pawlak, K. M. (2012) · Polish Journal of Surgery · doi:10.2478/v10035-012-0005-4 · Cited by 4
Role of 68Ga-DOTATOC PET/CT in Insulinoma According to 3 Different Contexts: A Retrospective Study
Moreau, P.-L., Aveline, C., Christin‐Maître, S., Chanson, P., Dubreuil, O., Rusu, T., & Montravers, F. (2022) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004126 · Cited by 4
“Copyright © 2022 Wolters Kluwer H The diagnosis of insulinoma is biologically based on the demonstration of endogenous hyperinsulinemic hypoglycemia during a 48-hour fasting test, which allows the diagnosis of organic hypoglycemia in 99% of cases.(6) Insulinoma is the main cause of endogenous hyperinsulinemic hypoglyc…”
BackgroundEndocrine pancreatic tumors: diagnosis and treatment
Tsolakis, A. V., & Janson, E. T. (2008) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.3.2.187 · Cited by 4
Tobón-Ospina, C., Castaño, P., Gutiérrez-Restrepo, J., Torres-Grajales, J. L., Duque, S. H., Cadavid, J. C. P., Gómez, J. R. M., & Román-Gonzaléz, A. (2020) · IATREIA · doi:10.17533/udea.iatreia.41 · Cited by 4
“Esta observación contrasta con lo reportado por la Clínica Mayo en Estados Unidos, en la que un 14 % de los pacientes desarrollaron hipoglucemia después de las 48 horas (14).”
Background
Metadata
- Authors
- Service, F. J., & Natt, N.
- Affiliations
- Mayo Clinic (US)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2000-11
- Volume
- 85
- Issue
- 11
- Pages
- 3973-3974
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1991309249
- Semantic Scholar
- 1f5c44abd64ff3b333eb7256b86405b956dc9f82
- Cited by
- 168
- References
- 5
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 8 · 2023: 10 · 2022: 12 · 2021: 5 · 2020: 4 · 2019: 6 · 2018: 7 · 2017: 10 · 2016: 6 · 2015: 10 · 2014: 10 · 2013: 5 · 2012: 9
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- insulinoma, prolonged fasting, hypoglycemia, diagnostic accuracy, fasting duration, plasma glucose, Mayo Clinic history
- MeSH terms
- Blood Glucose, Diagnosis, Differential, Fasting, Humans, Hyperinsulinism, Hypoglycemia, Insulinoma, Pancreatic Neoplasms, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.